Biotechnology
Insys Therapeutics Sinks After Filing for Bankruptcy
Insys says it will continue to operate its business 'in the ordinary course' while it sells off its assets through bankruptcy court.
Blindly Following the Consensus Is Rarely the Right Course of Action
That's why I always act incrementally when allocating new funds to the market or raising cash in my portfolio.
Stalking Entry Points in the XBI Biotech ETF
Plus an update on my SPX and Nike plays.
Mirati Therapeutics Could Soar Even Higher
Prices went vertical early this month on heavy volume.
Google's $2.6-Billion Deal for Looker Drives Home Its Big Cloud Ambitions
While Looker operates in a very competitive market, it does have some unique technology strengths that could be useful as Google tries to grow its enterprise cloud position.
Eli Lilly Takes Aim at Chronic Pain Problem, Alleviating Opiate Addiction
Eli Lilly's plan to eliminate pain could have farther reaching positive effects than just migraines.
Here's How Anxious Investors Can Hedge Against Fed Uncertainty
The Fed has given retail investors a run around in the past year. Here's the game-plan from here.
A Six-Pack of Biotech Best Bets
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
Nektar Therapeutics Jumps on Positive Results From Melanoma Treatment Study
The company says the test revealed patients were experiencing 'deepening and durability of response over time' with the treatment.
Amgen Shares Gain on Positive Lung-Cancer Trial Results
Shares of Amgen rise after the company announces positive initial trial results from its experimental drug used to treat non-small-cell lung cancer patients.